Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Deutsche Bank (ETR:DBKGn) began coverage on Neurocrine Biosciences (NASDAQ:NBIX) stock, assigning a Hold rating and setting a price target of $138. The bank's analyst noted that with a current market ...

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy ...

Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company ...

Guggenheim maintained a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) but lowered the price target to $163 from $165. The adjustment follows the company's fourth-quarter sales report, which ...

Needham & Company LLC reiterated their hold rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research report released on Friday,Benzinga reports. Several other equities ...

Deutsche Bank initiated coverage of Neurocrine (NBIX) with a Hold rating and $138 price target Maximize Your Portfolio with Data Driven ...

Shares of Neurocrine Biosciences Inc. plummeted 19 percent week-on-week to close Friday’s trading at $122.62 each as ...